Together, our internal development and manufacturing capabilities and external network cover the full spectrum of Chemistry, Manufacturing and Controls (CMC) activities for small and large molecules – from process, analytical, formulation, device and packaging development to pre-clinical, clinical and commercial drug substance, as well as drug product manufacturing, fill and finish, device assembly and packaging. These activities are performed across our sites and at selected partners and contract manufacturing organizations (CMOs).
We operate distribution centers worldwide for direct distribution of most of our commercial and clinical products. We also use third-party distributors to supplement distribution. Through our global supply chain organization, we ensure end-to-end oversight of supply – from raw material procurement to delivery in each of the countries where UCB delivers directly.
From the onset of the outbreak, UCB continuously monitored the situation for any potential impact to the supply of our medicines around the world, accelerating our cycles, tapping our strategic buffer stocks where necessary, and multi-sourcing key materials in our global manufacturing and supply network to anticipate and mitigate the impact of any potential disruptions due to the pandemic. We are proud that thanks to the efforts of colleagues and partners around the world, we ensured continuity of supply of our products to patients and our network of suppliers.